Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cedar

29.00
0.0000
Volume:- -
Turnover:- -
Market Cap:385.36M
PE:-2.57
High:29.00
Open:29.00
Low:29.00
Close:29.00
52wk High:29.00
52wk Low:29.00
Shares:13.29M
Float Shares:8.67M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.20
Dividend Rate:0.68%
EPS(TTM):-11.3005
EPS(LYR):-4.2358
ROE:-27.01%
ROA:1.48%
PB:1.61
PE(LYR):-6.85

Loading ...

Cedar Woods Properties Initiates Trading Halt Ahead of Dividend Announcement

TIPRANKS
·
Oct 13

CIBC to Transfer 11 CDR Listings to TSX

TIPRANKS
·
Oct 10

Cedar Woods Properties Limited Announces Cessation of Performance Rights

TIPRANKS
·
Oct 09

Toll Brothers Announces New Luxury Home Community Coming Soon to Cedar Park, Texas

GlobeNewswire
·
Oct 08

Cedar Woods Properties Expected to Grow NPAT by 10% in Fiscal 2026, Says Euroz Hartleys

MT Newswires Live
·
Oct 01

Condor Energies (CDR) Has a New Rating from Canaccord Genuity

TIPRANKS
·
Sep 30

Cedar Woods Announces 38th Annual General Meeting and Key Resolutions

TIPRANKS
·
Sep 26

Cedar Woods Announces Leadership Transition with New Company Secretary

TIPRANKS
·
Sep 18

Cedar Woods Properties' (ASX:CWP) Upcoming Dividend Will Be Larger Than Last Year's

Simply Wall St.
·
Sep 12

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

GlobeNewswire
·
Aug 30

Houston American Energy Corp. to Break Ground at Cedar Port in Q4 with Corvus Construction

GlobeNewswire
·
Aug 27

Cedar Woods Properties Posts Higher Fiscal 2025 Earnings, Revenue

MT Newswires Live
·
Aug 26

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

GlobeNewswire
·
Aug 25

Cedar Sees 1H Net Y104.00M

Dow Jones
·
Aug 12

Cedar Fair Q2 Adj. EPS $0.26 Down From $0.40 YoY

Benzinga
·
Aug 06

Cedar Fair Q2 Sales $930.39M Miss $1.05B Estimate

Benzinga
·
Aug 06

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

GlobeNewswire
·
Jul 29

Cedar Fair Is Maintained at Outperform by Mizuho

Dow Jones
·
Jul 18

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

GlobeNewswire
·
Jul 16

Cedar Fair Is Maintained at Buy by UBS

Dow Jones
·
Jul 15